Isatuximab

Jun 15, 2020

Sanofi's emerging oncology pipeline highlighted at the AACR Virtual Annual Meeting II

Mar 02, 2020

FDA approves Sarclisa® (isatuximab-irfc) for patients with relapsed refractory multiple myeloma

Mar 02, 2020

FDA approves Sarclisa® (isatuximab-irfc) for patients with relapsed refractory multiple myeloma

Mar 02, 2020

FDA approves Sarclisa® (isatuximab-irfc) for patients with relapsed refractory multiple myeloma

Mar 02, 2020

FDA Approves New Therapy for Patients with Previously Treated Multiple Myeloma

Mar 02, 2020

FDA Approves New Therapy for Patients with Previously Treated Multiple Myeloma

Mar 02, 2020

FDA Approves New Therapy for Patients with Previously Treated Multiple Myeloma

Jul 03, 2019

FDA approves new treatment for refractory multiple myeloma

Jun 19, 2019

World Multiple Myeloma Disease Coverage Forecast and Market 2018-2024: Leading Multiple Myeloma Drugs will Soon Face Generic Competition

Apr 29, 2019

I-Mab Biopharma and MorphoSys Announce First Patient Dosed in Phase 3 Clinical Study of TJ202/MOR202 in Multiple Myeloma

Feb 07, 2019

Sanofi delivers 2018 business EPS growth of 5.1% at CER

Dec 02, 2018

Oncopeptides Presents First Interim Data From the Ongoing Combination Trial ANCHOR With Melflufen at the 60th American Society of Hematology Meeting

Jun 07, 2018

Evolving Treatment Strategies in Multiple Myeloma: Janssen's Darzalex Leads a Host of Novel Agents in Redefining Treatment Strategies and Approaches